Hemab Q2 FY26 net loss widens to $24.15 million; R&D expenses rise to $20.34 million
Reuters2026/08/11 11:03- Hemab Therapeutics posted a Q2 net loss of $24.2 million, or $0.80 per share, versus a $12.2 million loss a year earlier.
- R&D expense rose to $20.3 million from $12.9 million year over year; G&A climbed to $5.7 million from $3.2 million.
- Cash, cash equivalents, and marketable securities jumped to $457.5 million from $163.5 million at March 31, boosted by $317.2 million IPO proceeds.
- FDA endorsed sutacimig’s GT data package to move into a Phase 3 pivotal trial at 0.2 mg/kg weekly, with initiation planned in 2H 2026.
- HMB-003 was unveiled for heavy menstrual bleeding, with first-in-human studies planned for 2H 2026 and initial clinical data targeted for mid-2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
